Sympathetic Nervous System Catecholamines and Neuropeptide Y Neurotransmitters Are Upregulated in Human NAFLD and Modulate the Fibrogenic Function of Hepatic Stellate Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Sigala, Barbara ^a   McKee, Chad ^a   Soeda, Junpei ^a   Pazienza, Valerio ^b   Morgan, Maelle ^a   Lin, Ching I ^a   Selden, Clare ^a   Vander Borght, Sara ^c   Mazzoccoli, Gianluigi ^b   Roskams, Tania ^c   Vinciguerra, Manlio ^a,b   Oben, Jude A ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA2; DOPAMINE BETA MONOOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRAZOSIN; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADRENALIN RELEASE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NORADRENALIN RELEASE; RECEPTOR UPREGULATION; STELLATE CELL;

BASE SEQUENCE; CATECHOLAMINES; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; DNA PRIMERS; FATTY LIVER; HEPATIC STELLATE CELLS; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; NEUROPEPTIDE Y; NOREPINEPHRINE; RECEPTORS, ADRENERGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYMPATHETIC NERVOUS SYSTEM; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84883319197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072928     Document Type: Article

References (39)

1. Lee Y, Friedman SL, (2010) Fibrosis in the liver: acute protection and chronic disease. Prog Mol Biol Transl Sci 97: 151-200.
2. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, et al. (2004) Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 53: 438-445.
3. Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, et al. (2006) Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 291: G877-884.
4. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, et al. (2003) Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 308: 284-292.
5. Oben JA, Yang S, Lin H, Ono M, Diehl AM, (2003) Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem Biophys Res Commun 302: 685-690.
6. Lundberg JM, Torssell L, Sollevi A, Pernow J, Theodorsson Norheim E, et al. (1985) Neuropeptide Y and sympathetic vascular control in man. Regul Pept 13: 41-52.
7. Cavadas C, Cefai D, Rosmaninho-Salgado J, Vieira-Coelho MA, Moura E, et al. (2006) Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion. Proc Natl Acad Sci U S A 103: 10497-10502.
8. Young JB, Landsberg L, (1977) Suppression of sympathetic nervous system during fasting. Science 196: 1473-1475.
9. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, et al. (2010) Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 285: 17271-17276.
10. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, et al. (1999) Neural mechanisms in human obesity-related hypertension. J Hypertens 17: 1125-1133.
11. Burt AD, Tiniakos D, MacSween RN, Griffiths MR, Wisse E, et al. (1989) Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liver. Hepatology 9: 839-845.
12. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol.
13. James O, Day C, (1999) Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353: 1634-1636.
14. Charlton M, (2004) Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2: 1048-1058.
15. Oben J, Nikolopoulos A, Paulon E (2008) Non Alcoholic Fatty Liver Disease CPD Bulletin- Biochemistry. 9: 47-53.
16. Rodriguez B, Torres DM, Harrison SA, (2012) Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 9: 726-731.
17. Soeda J, Morgan M, McKee C, Mouralidarane A, Lin C, et al. (2012) Nicotine induces fibrogenic changes in human liver via nicotinic acetylcholine receptors expressed on hepatic stellate cells. Biochem Biophys Res Commun 417: 17-22.
18. Oben JA, Yang S, Lin H, Ono M, Diehl AM, (2003) Acetylcholine promotes the proliferation and collagen gene expression of myofibroblastic hepatic stellate cells. Biochem Biophys Res Commun 300: 172-177.
19. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, et al. (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53: 810-820.
20. Pazienza V, Vinciguerra M, Andriulli A, Mangia A, (2010) Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 91: 1678-1686.
21. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, et al. (2012) Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165: 2325-2340.
22. Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, et al. (2013) Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes. PLoS One 8: e60527.
23. Rappa F, Greco A, Podrini C, Cappello F, Foti M, et al. (2013) Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. PLoS One 8: e54458.
24. Cassiman D, van Pelt J, De Vos R, Van Lommel F, Desmet V, et al. (1999) Synaptophysin: A novel marker for human and rat hepatic stellate cells. Am J Pathol 155: 1831-1839.
25. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, et al. (2008) Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab Invest 88: 973-985.
26. Saxena NK, Yang Y, Floyd J, Anania F, (2002) Leptin is mitogenic, anti-apoptotic and increases fibrogenic response genes in rat hepatic stellate cells. Hepatology 36 36: 316A.
27. Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, et al. (2007) Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 54: 2092-2098.
28. Borthwick LA, Wynn TA, Fisher AJ, (2013) Cytokine mediated tissue fibrosis. Biochim Biophys Acta 1832: 1049-1060.
29. Bonnefont-Rousselot D, Mahmoudi A, Mougenot N, Varoquaux O, Le Nahour G, et al. (2002) Catecholamine effects on cardiac remodelling, oxidative stress and fibrosis in experimental heart failure. Redox Rep 7: 145-151.
30. Sivamani RK, Lam ST, Isseroff RR (2007) Beta adrenergic receptors in keratinocytes. Dermatol Clin 25: 643-653, x.
31. Galuppo M, Esposito E, Mazzon E, Di Paola R, Paterniti I, et al. (2011) MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn Schmiedebergs Arch Pharmacol 384: 21-37.
32. Marra F, (1999) Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31: 1120-1130.
33. Schwabe RF, Schnabl B, Kweon YO, Brenner DA, (2001) CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 166: 6812-6819.
34. Strack I, Schulte S, Varnholt H, Schievenbusch S, Tox U, et al. (2011) beta-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 91: 252-261.
35. Zapater P, Gomez-Hurtado I, Peiro G, Gonzalez-Navajas JM, Garcia I, et al. (2012) Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. PLoS One 7: e43371.
36. Vasina V, Giannone F, Domenicali M, Latorre R, Berzigotti A, et al. (2012) Portal hypertension and liver cirrhosis in rats: effect of the beta3-adrenoceptor agonist SR58611A. Br J Pharmacol 167: 1137-1147.
37. Trebicka J, Hennenberg M, Schulze Probsting A, Laleman W, Klein S, et al. (2009) Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 50: 1924-1935.
38. Theocharidou E, Krag A, Bendtsen F, Moller S, Burroughs AK, (2012) Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. Liver Int 32: 1327-1332.
39. Moller S, Henriksen JH, (2010) Cirrhotic cardiomyopathy. J Hepatol 53: 179-190.